Literature DB >> 15053046

Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.

Young-Il Jo1, Jae-Ho Yoon, Sang-Youl Shin, Won-Chul Chang, Byung-Kook Kim, Choon-Jo Jin, Jong-Oh Song.   

Abstract

Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients. We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia. The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15053046      PMCID: PMC4531552          DOI: 10.3904/kjim.2004.19.1.58

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  14 in total

1.  Nonchemotherapy drug-induced agranulocytosis: interest of haematopoietic growth factors.

Authors:  E Andrès; E Noel; F Maloisel
Journal:  J Intern Med       Date:  2002-06       Impact factor: 8.989

2.  Prognostic factors of hematologic recovery in nonchemotherapy drug-induced agranulocytosis.

Authors:  Frédéric Maloisel; Emmanuel Andrès; Georges Kaltenbach; Esther Noel; Argyro Koumarianou
Journal:  Haematologica       Date:  2003-04       Impact factor: 9.941

3.  Agranulocytosis associated with cephalosporin.

Authors:  C H Hui; L C Chan
Journal:  BMJ       Date:  1993-08-21

4.  Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor.

Authors:  Emmanuel Andrès; Jean Emmanuel Kurtz; Catherine Martin-Hunyadi; Georges Kaltenbach; Martine Alt; Jean Christophe Weber; Jean Sibilia; Jean Louis Schlienger; Patrick Dufour; F rédéric Maloisel
Journal:  Am J Med       Date:  2002-04-15       Impact factor: 4.965

5.  Agranulocytosis induced by vancomycin or ticarcillin/clavulanate.

Authors:  D L Mandl; M W Garrison; S D Palpant
Journal:  Ann Pharmacother       Date:  1997-11       Impact factor: 3.154

6.  Agranulocytosis related to vancomycin therapy.

Authors:  A Adrouny; S Meguerditchian; C H Koo; M Gadallah; S Rasgon; M Idroos; E Oppenheimer; M Glowalla
Journal:  Am J Med       Date:  1986-12       Impact factor: 4.965

7.  Prolonged vancomycin-associated neutropenia in a chronic hemodialysis patient.

Authors:  S Milsteen; R Welik; M R Heyman
Journal:  Am J Med Sci       Date:  1987-08       Impact factor: 2.378

8.  Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes.

Authors:  A Juliá; M Olona; J Bueno; E Revilla; J Rosselló; J Petit; M Morey; A Flores; L Font; J Maciá
Journal:  Br J Haematol       Date:  1991-11       Impact factor: 6.998

9.  Aztreonam-induced myelosuppression during treatment of Pseudomonas aeruginosa pneumonia.

Authors:  M M Dallal; J S Czachor
Journal:  DICP       Date:  1991-06

10.  Effects of ceftazidime, a betalactam antibiotic, on murine haemopoiesis in vitro.

Authors:  S P Hauser; K B Udupa; D A Lipschitz
Journal:  Br J Haematol       Date:  1994-04       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.